The U.S. Food and Drug Administration on December 3 authorized the use of Eli Lilly’s Covid-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness.

The U.S. Food and Drug Administration approved Covid-19 vaccine booster shots for all Americans ages 18 and over Friday morning.  

The U.S. government on Feb. 27 authorized Johnson & Johnson’s single-dose Covid-19 vaccine, enabling millions more Americans to be vaccinated in the coming weeks and setting the vaccine up for additional approvals around the world.

Merck & Co.

Merck will have to wait to see if a Covid-19 therapeutic gained in November through the $425 million acquisition of OncoImmune can receive Emergency Use Authorization (EUA) after the U.S. Food and Drug Administration requested additional data beyond the Phase III study announced during 2020

The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) to a combination of Eli Lilly and AbCellera’s monoclonal antibody bamlanivimab and the Lilly antibody etesevimab for mild to moderate Covid-19.

Eli Lilly and Co. will move a new Covid-19 antibody therapy to human trials targeting a coronavirus variant that was first found in South Africa, the U.S. drugmaker said.

Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.

The Covid-19 vaccine developed by British drugmaker AstraZeneca Plc and Oxford University will likely be authorized for emergency use in the United States in April 2021, the chief adviser for the U.S. Covid-19 vaccine program said.

The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.

The first injections of Moderna’s Covid-19 vaccine started to be administered on Dec. 21 after the U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) on Dec. 18.